Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
Clinical Ovarian Cancer and Other Gynecologic Malignancies
|
August 12, 2011
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma
Neil S Horowitz, Richard T Penson, Dan G Duda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
Ursula A Matulonis, Neil S Horowitz, Susana M Campos, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 27, 2013
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer
Jose Alejandro Rauh-Hain, Stephanie H Guseh, Katharine M Esselen, et al.
Gynecologic Oncology
|
July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N Krasner, Susana M Campos, Chantay L Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
Richard T Penson, Don S Dizon, Stephen A Cannistra, et al.
Gynecologic Oncology
|
February 16, 2019
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin
C N Krasner, C Castro, R T Penson, et al.
Gynecologic Oncology
|
March 27, 2016
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer
R T Penson, E Sales, L Sullivan, et al.
Gynecologic Oncology
|
January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
L R Duska, C N Krasner, D M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 26, 2014
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study
Jonathan S Berek, Robert P Edwards, Lynn P Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
Clinical Ovarian Cancer and Other Gynecologic Malignancies
|
August 12, 2011
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma
Neil S Horowitz, Richard T Penson, Dan G Duda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
Ursula A Matulonis, Neil S Horowitz, Susana M Campos, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 27, 2013
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer
Jose Alejandro Rauh-Hain, Stephanie H Guseh, Katharine M Esselen, et al.
Gynecologic Oncology
|
July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N Krasner, Susana M Campos, Chantay L Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
Richard T Penson, Don S Dizon, Stephen A Cannistra, et al.
Gynecologic Oncology
|
February 16, 2019
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin
C N Krasner, C Castro, R T Penson, et al.
Gynecologic Oncology
|
March 27, 2016
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer
R T Penson, E Sales, L Sullivan, et al.
Gynecologic Oncology
|
January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
L R Duska, C N Krasner, D M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 26, 2014
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study
Jonathan S Berek, Robert P Edwards, Lynn P Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.
Page
of 11